NATCO Pharma Limited announces launch of the first generic version of Revlimid® (Lenalidomide capsules) in 5 mg, 10 mg, 15 mg, and 25 mg strengths in the U.S. market on 07th March 2022
The above strengths of lenalidomide capsules are prescribed in adults for the treatment of
- Multiple myeloma in combination with the medicine dexamethasone
- Certain myelodysplastic syndromes and
- Mantle cell lymphoma following specific prior treatment. For more information refer to the prescribing information or other medical resources.
NATCO Pharma Limited launch Revlimid® along with its marketing partner Arrow International Ltd (an affiliate of Teva Pharmaceutical Industries Ltd).
NATCO and Teva are launching these strengths of lenalidomide pursuant to a license of patents owned by Celgene (now part of Bristol-Myers Squibb).
